Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020

Olivier Lortholary, Mario Fernandez-Ruiz, John W. Baddley, Oriol Manuel, Xavier Mariette, Kevin L. Winthrop

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Biological therapies have improved the outcomes of several major inflammatory, autoimmune and also neoplastic disorders. Those directed towards cytokines or other soluble mediators, cell-surface molecules or receptors or various components of intracellular signalling pathways may be associated with the occurrence of infections whose diversity depends on the particular immune target. In this context and following a keynote lecture given by one of us at the European League Against Rheumatism meeting on June 2018, a multidisciplinary group of experts deeply involved in the use of targeted and biological therapies in rheumatoid and psoriatic arthritis decided to summarise their recent vision of the immunological basis and epidemiology of infections occurring during targeted and biological therapies, and provide useful indications for their management and prevention.

Original languageEnglish (US)
Pages (from-to)1532-1543
Number of pages12
JournalAnnals of the rheumatic diseases
Volume79
Issue number12
DOIs
StatePublished - Dec 1 2020

Keywords

  • DMARDs (biologic)
  • infections
  • psoriatic arthritis
  • rheumatoid arthritis
  • vaccination

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020'. Together they form a unique fingerprint.

Cite this